September 12th 2025
Merck reported the results for its phase 3 trial for its vaccine, Capvaxive, which was found to be noninferior to the pneumococcal 23-valent polysaccharide vaccine (PPSV23) for each of the 12 serotypes shared between the vaccines.
Community Acquired Pneumonia Often Inappropriately Diagnosed in Hospital Admissions
April 2nd 2024Community acquired pneumonia is often inappropriately diagnosed in hospital admissions, particularly among older adults with dementia, and can lead to in-hospital antibiotic-associated adverse events, such as Clostridioides difficile.
Read More
Few Readmissions After Hospitalization for CAP Are Avoidable
April 18th 2022An analysis of readmissions after hospitalization with community-acquired pneumonia (CAP) in France found that few readmissions were avoidable, supporting criticism that the measure may lead to unfair penalties under pay-for-performance programs.
Read More